XFORX4 Pharmaceuticals, Inc同业对比
X4 Pharmaceuticals, Inc 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XFOR本股 | $311M#9 | 2.2x#1 | 2.0x#10 | 8.9x#3 | 1273.2%#2 | -111.5%#12 | -247.4%#3 | -50.9%#7 | -582.0%#4 | — | -20.6%#11 | — |
| ALLO | $390M#1 | — | 0.9x#2 | — | -100.0%#9 | 25.9%#5 | — | -43.8%#6 | — | — | 3.2%#8 | — |
| ZURA | $383M#2 | — | 3.8x#11 | — | — | -31.0%#11 | — | -67.6%#8 | — | — | 15.5%#7 | — |
| TECX | $380M#3 | — | 1.7x#8 | — | — | -27.9%#10 | — | -33125.9%#12 | -713.5%#5 | — | 15.9%#6 | — |
| CCCC | $373M#4 | — | 1.5x#6 | 10.4x#4 | 1.0%#6 | 0.3%#6 | -320.5%#5 | -42.5%#4 | — | — | 34.9%#5 | — |
| SRZN | $363M#5 | — | — | 104.3x#8 | -67.4%#8 | -280.8%#14 | -1210.6%#6 | — | — | — | 120.4%#2 | — |
| KYTX | $313M#6 | — | 1.9x#9 | — | — | -26.5%#9 | — | -97.4%#10 | -107.1%#3 | — | -20.1%#10 | — |
| SCTX | $311M#7 | — | — | — | — | — | — | — | — | — | — | — |
| AGEN | $311M#8 | 2.3x#2 | — | 2.7x#2 | 10.4%#4 | 98.7%#2 | -17.7%#2 | — | — | — | 85.4%#3 | — |
| SABS | $298M#10 | 13.7x#3 | 1.4x#5 | — | -100.0%#9 | 138.9%#1 | — | 6.2%#1 | — | — | 0.9%#9 | — |
| IPSC | $297M#11 | — | 1.3x#4 | 2.7x#1 | 1556.8%#1 | 92.4%#3 | -15.8%#1 | -4.1%#3 | -9.3%#1 | — | 187.6%#1 | — |
| EIKN | $292M#12 | — | 0.6x#1 | — | — | — | — | 0.0%#2 | — | — | — | — |
| OCGN | $271M#13 | — | — | 61.3x#7 | 8.8%#5 | -25.9%#8 | -1425.7%#7 | — | — | — | -44.0%#13 | — |
| LXEO | $264M#15 | — | 1.1x#3 | 404.0x#9 | — | -1.7%#7 | -16706.0%#9 | -42.5%#5 | — | — | -61.4%#14 | — |
| LCTX | $264M#14 | — | 4.3x#12 | 18.2x#5 | 53.2%#3 | -241.4%#13 | -251.6%#4 | -104.3%#11 | — | — | -42.4%#12 | — |
| FATE | $246M#16 | — | 1.6x#7 | 37.0x#6 | -51.2%#7 | 26.8%#4 | -2222.4%#8 | -88.8%#9 | -102.3%#2 | — | 71.5%#4 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议